Michael J Rosanoff1, Ruth Ottman. 1. G.H. Sergievsky Center, Columbia University, 630 W. 168th Street, P&S Box 16, New York, NY 10032, USA. ro6@columbia.edu
Abstract
BACKGROUND: Assessment of the penetrance of disease-causing mutations is extremely important for developing clinical applications of gene discovery, such as genetic testing and counseling. Mutations in the leucine-rich, glioma inactivated 1 gene (LGI1) have been identified in about 50% of families with autosomal dominant partial epilepsy with auditory features (ADPEAF), but estimates of LGI1 mutation penetrance have ranged widely, from 50 to 85%. The current study aimed to provide a more precise estimate of LGI1 mutation penetrance. METHODS: We analyzed data from all 24 previously published ADPEAF families with mutations in LGI1. To estimate penetrance, we used the information from the published pedigree figures to determine the proportion of obligate carriers who were affected. We assessed whether penetrance was associated with the total number of affected individuals in each family, or mutation type (truncating or missense) or location within the gene. We also compared penetrance in males and females, and among different generations within the families. RESULTS: Overall penetrance was 67% (95% CI 55-77%), and did not vary according to mutation type or location within the gene. Penetrance was greater in families with more affected individuals, but this trend was not significant. Penetrance did not differ by gender but increased with advancing generation, probably because of limited information about early generations. CONCLUSIONS: Our results suggest that about two-thirds of individuals who inherit a mutation in LGI1 will develop epilepsy. This probably overestimates the true penetrance in the population because it is based on data from families containing multiple affected individuals.
BACKGROUND: Assessment of the penetrance of disease-causing mutations is extremely important for developing clinical applications of gene discovery, such as genetic testing and counseling. Mutations in the leucine-rich, glioma inactivated 1 gene (LGI1) have been identified in about 50% of families with autosomal dominant partial epilepsy with auditory features (ADPEAF), but estimates of LGI1 mutation penetrance have ranged widely, from 50 to 85%. The current study aimed to provide a more precise estimate of LGI1 mutation penetrance. METHODS: We analyzed data from all 24 previously published ADPEAF families with mutations in LGI1. To estimate penetrance, we used the information from the published pedigree figures to determine the proportion of obligate carriers who were affected. We assessed whether penetrance was associated with the total number of affected individuals in each family, or mutation type (truncating or missense) or location within the gene. We also compared penetrance in males and females, and among different generations within the families. RESULTS: Overall penetrance was 67% (95% CI 55-77%), and did not vary according to mutation type or location within the gene. Penetrance was greater in families with more affected individuals, but this trend was not significant. Penetrance did not differ by gender but increased with advancing generation, probably because of limited information about early generations. CONCLUSIONS: Our results suggest that about two-thirds of individuals who inherit a mutation in LGI1 will develop epilepsy. This probably overestimates the true penetrance in the population because it is based on data from families containing multiple affected individuals.
Authors: Melodie R Winawer; Filippo Martinelli Boneschi; Christie Barker-Cummings; Joseph H Lee; Jianjun Liu; Constantine Mekios; T Conrad Gilliam; Timothy A Pedley; W Allen Hauser; Ruth Ottman Journal: Epilepsia Date: 2002-01 Impact factor: 5.864
Authors: José M Morante-Redolat; Ana Gorostidi-Pagola; Salomé Piquer-Sirerol; Amets Sáenz; Juan J Poza; Juan Galán; Stefan Gesk; Theologia Sarafidou; Victor-F Mautner; Simona Binelli; Eike Staub; Bernd Hinzmann; Lisa French; Jean-F Prud'homme; Daniela Passarelli; Paolo Scannapieco; Carlo A Tassinari; Giuliano Avanzini; José F Martí-Massó; Lan Kluwe; Panagiotis Deloukas; Nicholas K Moschonas; Roberto Michelucci; Reiner Siebert; Carlo Nobile; Jordi Pérez-Tur; Adolfo López de Munain Journal: Hum Mol Genet Date: 2002-05-01 Impact factor: 6.150
Authors: Antonio Pizzuti; Elisabetta Flex; Carlo Di Bonaventura; Tania Dottorini; Gabriella Egeo; Mario Manfredi; Bruno Dallapiccola; Anna Teresa Giallonardo Journal: Ann Neurol Date: 2003-03 Impact factor: 10.422
Authors: Eliane Kobayashi; Neide F Santos; Fabio R Torres; Rodrigo Secolin; Luiz A C Sardinha; Iscia Lopez-Cendes; Fernando Cendes Journal: Arch Neurol Date: 2003-11
Authors: Roberto Michelucci; Juan Jose Poza; Vito Sofia; Maria Rita de Feo; Simona Binelli; Francesca Bisulli; Evan Scudellaro; Barbara Simionati; Rosanna Zimbello; Giuseppe D'Orsi; Daniela Passarelli; Patrizia Avoni; Giuliano Avanzini; Paolo Tinuper; Roberto Biondi; Giorgio Valle; Victor F Mautner; Ulrich Stephani; Carlo Alberto Tassinari; Nicholas K Moschonas; Reiner Siebert; Adolpho Lopez de Munain; Jordi Perez-Tur; Carlo Nobile Journal: Epilepsia Date: 2003-10 Impact factor: 5.864
Authors: Gary A Heiman; Kay Kamberakis; Richard Gill; Sergey Kalachikov; Timothy A Pedley; W Allen Hauser; Ruth Ottman Journal: Epilepsia Date: 2010-07-26 Impact factor: 5.864
Authors: Karl Martin Klein; Manuela Pendziwiat; Rony Cohen; Silke Appenzeller; Carolien G F de Kovel; Felix Rosenow; Bobby P C Koeleman; Gregor Kuhlenbäumer; Liron Sheintuch; Ronel Veksler; Alon Friedman; Zaid Afawi; Ingo Helbig Journal: J Neurol Date: 2015-10-12 Impact factor: 4.849
Authors: R Ottman; L Rosenberger; A Bagic; K Kamberakis; E K Ritzl; A M Wohlschlager; S Shamim; S Sato; C Liew; W D Gaillard; E Wiggs; M M Berl; P Reeves-Tyer; E H Baker; J A Butman; W H Theodore Journal: Neurology Date: 2008-12-09 Impact factor: 9.910